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Abstract
Introduction: Current knowledge indicates that there is a close connection between being overweight, obesity and iron metabolism disor-
ders, but the underlying mechanism is unclear. Hepcidin could be a major contributor to poor iron status observed in the obese population. 
Material and methods: The study was performed in 58 obese elderly individuals (F/M 34/24) aged 65-91 (78.92 ± 8.32) years. The control 
group consisted of 15 non-obese elderly volunteers, age- and sex-matched. Based on the WHO definition, 36 (62%) obese individuals 
were diagnosed with normo- or microcytic anaemia. The following parameters were determined: prohepcidin, haemoglobin, serum iron, 
erythropoietin, ferritin and C-reactive protein (CRP).
Results: Prohepcidin concentrations were significantly increased in obese elderly individuals without anaemia compared to obese and 
anaemic (p < 0.01) as well as non-obese volunteers (p < 0.01). In obese individuals with anaemia there was a decrease in serum iron, 
concomitant with increased levels of erythropoietin and CRP compared to two other groups. Ferritin concentration was increased in 
obese people (with and without anaemia) compared to the non-obese group. Serum prohepcidin levels were positively correlated with 
fat mass percentage in obese individuals without and with anaemia (r = 0.32; p = 0.02).
Conclusion: Results of this preliminary study suggest that body fat content does have an impact on prohepcidin concentration, and 
thereby on iron homeostasis. (Endokrynol Pol 2013; 64 (4): 272–277)
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Streszczenie
Wstęp: Obecny stan wiedzy wskazuje na ścisły związek pomiędzy nadwagą czy otyłością a zaburzeniami metabolizmu żelaza. Jednakże mecha-
nizm tej zależności nie jest wyjaśniony. Hepcydyna może być istotnym czynnikiem niedoborów żelaza obserwowanych w populacji osób otyłych. 
Materiał i metody: Badanie zrealizowano wśród 58 otyłych osób (K/M 34/24), w wieku 65–91 lat (78,92 ± 8,32 lat). Grupę kontrolną sta-
nowiło 15 zdrowych ochotników z prawidłową masą ciała, dobranych odpowiednio pod względem wieku i płci. Na podstawie definicji 
WHO, u 36 (62%) otyłych pacjentów zdiagnozowano niedokrwistości normo lub mikrocytową. W ramach badań oznaczono następujące 
parametry: prohepcydynę, hemoglobinę, stężenie żelaza, ferrytyny i erytropoetyny, białka C-reaktywnego (CRP).
Wyniki: Wykazano istotnie wyższe stężenie surowiczej prohepcydyny w grupie pacjentów otyłych bez niedokrwistości (p < 0,01) 
w porównaniu z wartościami obserwowanymi u pacjentów otyłych z niedokrwistością oraz u osób z grupy kontrolnej z prawidłową 
masą ciała (p < 0,01). U osób otyłych z niedokrwistością, obserwowano obniżone stężenie żelaza przy jednocześnie podwyższonych 
wartościach erytropoetyny oraz białka CRP w porównaniu z pozostałymi dwoma analizowanymi grupami. Stężenie ferrytyny było 
wyższe u pacjentów otyłych (zarówno z niedokrwistością oraz bez niedokrwistości) w odniesieniu do osób bez cech otyłości. W grupie 
pacjentów otyłych zarówno z niedokrwistością jak też bez niedokrwistości surowicza prohepcydyna pozytywnie korelowała z procentową 
zawartością tkanki tłuszczowej (r = 0,32; p = 0,02).
Wnioski: Wyniki wstępnych badań sugerują, że tkanka tłuszczowa może mieć wpływ na stężenie surowiczej prohepcydyny a tym samym 
również na ogólnoustrojową homeostazę żelaza. (Endokrynol Pol 2013; 64 (4): 272–277)
Słowa kluczowe: metabolizm żelaza, otyłość, prohepcydyna
Introduction
Current knowledge indicates that there is a close con-
nection between being overweight, obesity and iron 
metabolism disorders, but the underlying mechanism 
is unclear [1–6]. It has been noticed that the diet of 
obese people consists mainly of high fat and high car-
bohydrate meals with low value of Index of Nutritional 
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Quality [INQ] for iron [7, 8]. Moreover, the hypofer-
remia development in obese individuals could be a 
consequence of obesity-associated low-grade inflam-
mation [9, 10]. Adipose tissue is a very active endocrine 
organ secreting numerous hormones and cytokines 
associated with important systemic effects on differ-
ent metabolic processes [9, 10]. Studies available in the 
literature indicate that adipose tissue of obese patients 
produced an increased amount of proinflammatory 
cytokines contributing to the development of a low-
grade systemic inflammation in these patients [7, 10]. 
Research by Bekri et al. [5] pointed out that adipo-
cytes are the direct source of hepcidin, a peptide made 
up of 25 amino acids that plays a central role in the 
regulation of iron homeostasis. The major action of 
hepcidin is to internalise and degrade the iron efflux 
transporter ferroportin expressed on all iron-exporting 
cells [11]. So, a high hepcidin level leads to the sup-
pression of intestinal iron absorption and iron release 
from macrophages and hepatocytes, whereas a low 
concentration of hepcidin leads to acceleration of iron 
release from these cells [11–16]. As a result, increased 
hepcidin production may cause sideropenia [15, 16]. 
Hepcidin is a peptide synthesised mainly in the liver 
[17–19]. Hepatic hepcidin gene expression is more re-
sponsive to changes in erythropoiesis activity or iron 
intake rather than to changes in body iron stores [20–22]. 
It remains unknown whether the same regulatory 
factors also control the ‘adipose tissue-derived pool of 
hepcidin’. Recent studies indicate that IL-6, leptin and 
other inflammatory mediators may increase hepcidin 
concentration in human serum through the JAK2/ 
/STAT3 signalling pathway [6, 23]. Obesity-related low 
grade inflammation followed by increasing hepcidin 
concentration may reduce iron bio-availability [18–19]. 
Therefore, hepcidin could be a major contributor to 
poor iron status observed in the obese population. 
The aim of this work was to compare serum pro-
hepcidin and iron metabolism parameters in obese and 
non-obese elderly individuals.
Material and methods
The study group consisted of 58 obese elderly individu-
als (24 males, 34 females) between 65 and 91 years of 
age (mean age of 78.92 ± 8.32) admitted to the Depart-
ment and Clinic of Geriatrics, Nicolaus Copernicus 
University in Toruń, Collegium Medicum in Bydgoszcz. 
Obesity was defined as a fat mass percentage (%FM) 
≥ 25% in males and ≥ 33% in females [24]. Men with 
a %FM = 17–25% and women with a %FM = 22–33% 
were classified as normal body fat content (non-obese). 
Based on the Hgb levels below 12 g/dL in females and 
13 g/dL in males (WHO criteria), 36 obese individuals 
(62%) were diagnosed with normo- or microcytic anae-
mia. For this reason, the study group of obese individu-
als was divided into two subgroups: Group I — obese, 
without anaemia N = 22, and Group II — obese, with 
anaemia N = 36.
The peripheral blood samples were taken after the 
diagnosis of anaemia had been made, but prior to treat-
ment being provided.
The control group consisted of 15 healthy non-obese 
elderly volunteers (F/M 9/6) between 55 and 78 years 
of age (mean age of 66.57 ± 8.81), who came to the 
outpatient geriatric clinic in order to perform a complex 
geriatric examination (Group III). 
We excluded from the control group those people 
who had chronic inflammatory diseases and patients 
with: anaemia, undernutrition, cancer, rheumatic disor-
ders, inflammatory bowel diseases, endocrine diseases 
and those treated with steroid or non-steroidal anti-
inflammatory drugs.
Anyone who had taken any vitamin or mineral sup-
plements was excluded from the research.
All procedures in the study were approved by the 
Local Ethics Committee. Informed written consent was 
obtained after the purpose, nature, and potential risks 
had been explained to the subjects.
Analytical methods
Serum was stored at –80°C until analyses. Levels of pro-
hepcidin were determined by a stable enzyme-linked im-
munosorbent assay (ELISA) (DRG Instruments GmbH, 
Germany). Serum ferritin was quantified using the DRG 
Ferritin kit (EIA-1872, DRG International, Inc., USA). Se-
rum erythropoietin was determined by the EPO ELISA 
kit (Roche Diagnostics GmbH, Mannheim, Germany). 
Serum iron concentration was measured on the 
Architect c8000 System (Abbott Laboratories, IL, USA). 
C-reactive protein concentration in serum was deter-
mined by using BNTMII Systems (Dade Behring). Hae-
moglobin concentration was analysed in the routine 
diagnostic by using the Sysmex XE-2100.
Nutritional status was carried out based on the 
measurements of body mass (kg), body height (cm) 
and thickness of four skinfolds (mm): over biceps (BSF), 
triceps (TSF), suprailiac (SISF) and subscapular (SCSF). 
The body mass measurement was carried out using 
a Radwag physician scale, with electronic reading scale 
and measurement accuracy of 0.01 kg. Height was 
measured, and skinfolds thickness using a skinfold 
caliper made by Siber Hegner & Co. Ltd (measurement 
accuracy of 0.1 cm). The body mass index (BMI) was 
calculated by dividing the weight by the height squared 
(kg/m2). Fat mass percentage in the body (%FM) was 
calculated on the basis of weight measurements and 
the sum of four skinfolds thickness, according to the 
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Durnin and Wormsley formula [25]. The values of 
somatic parameters were interpreted for each person 
individually according to sex with reference [24, 25].
Statistical analysis
All statistics were conducted using Statistica software, 
version 8.0 (Stat-soft, Krakow, Poland). The normal dis-
tribution of variables was evaluated using W-Shapiro-
Wilk test. Results are presented as mean ± standard 
deviation (SD) when the data demonstrated a normal 
distribution, or as medians [Q1 (lower quartile) to Q3 
(upper quartile)] due to their being abnormally skew 
of the data. The following statistical tests were used in 
the study: one-way ANOVA and post-hoc tests. The 
relationships between the examined parameters were 
determined by Spearman’s rank-order correlation. A p 
value of < 0.05 was considered statistically significant. 
Results
There were non-significant differences in levels of hae-
matological and biochemical parameters between all 
the study groups as regards sex (p > 0.05). Therefore, 
the study results do not take into account the statistical 
distribution of sex. As expected, mean values of the fat 
mass percentage in the body (%FM) were significantly 
higher in the obese elderly patients (with anaemia and 
without anaemia) compared to healthy non-obese con-
trols. Similarly, mean BMIs were significantly greater in 
the obese groups (with anaemia and without anaemia) 
compared to the controls. The haemoglobin concentra-
tion in obese patients with anaemia was the lowest 
among all groups (Table I). 
In our study we demonstrated that prohepcidin con-
centrations were significantly increased in obese elderly 
Table I. Prohepcidin and iron metabolism parameters in the study subgroups and control group
Tabela I. Prohepcydyna oraz parametry gospodarki żelazowej w badanych podgrupach oraz w grupie kontrolnej
Parameter* Study groups Control group p
Obese 
no anaemia 
I (N = 22)
Obese 
with anaemia 
II (N = 36)
Non-obese 
no anaemia 
III (N = 15)
%FM
(%)
40.01 ± 5.98 36.32 ± 5.34 22.75 ± 4.69 NS I–II
0.0261 II–III
0.0009 I–III
BMI
[kg/m2]
31.86 ± 4.75 29.51 ± 5.46 26.28 ± 1.67 NS I–II
0.0395 II–III
0.0182 I–III
Haemoglobin
[g/dL]
14.12 ± 1.36 10.81 ± 1.49 13.43 ± 0.77  < 0.0001 I–II
 < 0.0001 II–III
NS I–III
Prohepcidin
[ng/mL]
293.29
(262.8; 370.7)
224.85
(188.7; 240.4)
151.38
(128.4; 241.7)
0.0033 I–II
NS II–III
0.0005 I-III
Iron 
[μg/dL]
80.95
(70.00; 98.00
35.00
(22.25; 62.70)
80.00
(40.00; 106.0)
 < 0.0001 I-II
0.0015 II–III
NS I–III
Ferritin
[ng/mL]
41.72
(27.77; 75.5)
57.48
(19.60; 134.6)
11.40
(9.26; 15.70)
NS I–II
0.0046 II–III
0.0151 I–III
EPO 
[U/L]
4.74
(3.76; 8.11)
8.95
(5.36; 13.87)
3.68
(1.76; 5.60)
0.0277 I–II
0.0024 II–III
NS IVIII
CRP 
[mg/L]
3.19
(3.00; 5.00)
8.85
(5.50; 41.90)
3.0
(3.0; 3.09)
0.0012 I–II
 < 0.0001 II–III
NS I–III
*Results are reported as mean ± SD (standard deviation) or medians (Q1; Q3) Q1 and Q3 – 25th and 75th percentiles. p — significance level; N — sample size; NS — 
differences not significant; %FM — fat mass percentage; BMI — body mass index; EPO — erythropoietin; CRP — C-reactive protein
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individuals without anaemia (Group I) (Me = 293.29 
ng/mL) compared to obese and anaemic individuals 
(Group II) (Me = 224.85 ng/mL) as well as non-obese 
volunteers (Group III) (Me = 151.38 ng/mL). There were 
non-significant differences between obese patients with 
anaemia and non-obese controls regarding prohepcidin 
levels (p > 0.05).
Both EPO and CRP were significantly higher in 
elderly obese patients with anaemia (Group II) com-
pared to the obese non-anaemic patients as well as the 
controls (Table I). No significant difference in serum 
EPO and CRP concentrations was found between obese 
non-anaemic and non-obese non-anaemic patients. 
Similarly, no statistically significant difference in iron 
concentrations was found among these two groups 
(I and III). The concentration of iron was the lowest 
in the group of obese patients with anaemia. Elevated 
ferritin levels were found in the patients with obesity 
(with anaemia (57.48 ng/mL) and without anaemia 
(41.72 ng/mL) compared to non-obese individuals 
(11.40 ng/mL) (Table I).
In the whole group of obese individuals, with and 
without anaemia, serum prohepcidin levels were 
positively correlated with fat mass percentage (r = 0.32; 
p = 0.02) (Fig. 1). In the group of non-obese elderly 
patients, prohepcidin was not related to any param-
eters studied.
Discussion
Obesity is defined as an excess of body fat, which 
increases the risk of many diseases and premature 
mortality. Currently, the most commonly used diag-
nostic indicator of obesity is body mass index (BMI). 
In addition, BMI has been widely used and accepted 
as a simple method to classify medical risk by weight 
status. The results show that BMI provides a measure of 
the relation between height and weight and correlates 
with body fat percentage in young and middle-aged 
adults [26–28]. In elderly people, age-related changes 
in body composition (i.e. decrease in lean body mass 
and increase in fat mass) and loss of height caused 
by compression of vertebral bodies and kyphosis [26, 
28–29] alter the relation between BMI and percentage 
body fat. In addition, especially for those in late old age 
and / or very late or hospitalised patients, are observed 
disturbances in water and electrolyte balance. In view 
of this, we must remember that dehydration will af-
fect weight loss and decrease in BMI. On the contrary, 
hyperhydration, which may be the result of, inter alia, 
too intensive fluid therapy, will increase BMI value. 
Therefore, changes in body composition would tend to 
underestimate fatness, whereas the loss of height would 
tend to overestimate fatness. Therefore, in our study, 
obesity was defined based on the individual values 
of the percentage of body fat (Durnin and Wormsley 
formula) [25].
An obesity impact on the prohepcidin level was 
observed for the first time by Lainé et al., who reported 
that obese women with classical haemochromatosis do 
not have a phenotypic expression of the disease. They 
suggested that the adipose tissue, via a yet unknown 
mechanism involving hepcidin, can affect iron homeo-
stasis [30]. This hypothesis was proven a year later by 
Bekri et al.’s research on the in vitro human adipocytes 
culture [5]. These authors discovered that hepcidin is a 
pro-inflammatory adipokine having great importance 
in sideropenia development in obese patients. They ob-
served increases of hepcidin mRNA level and hepcidin 
concentration, in adipose tissue. Additionally, hepcidin 
mRNA expression was observed to positively correlate 
with IL-6 and C-reactive protein concentrations, and 
to increase in the adipose tissue of considerably obese 
patients [5]. A complementary study was performed 
by Chung et al., where it was demonstrated that a line 
of human hepatoma cells [HuH7] treated with leptin 
resulted in the increase of hepcidin expression, depend-
ing on both exposition time and the leptin dosage [6]. 
Leptin, a hormone secreted by the white adipocytes, 
up-regulated hepcidin gene expression by means of 
leptin receptor [Ob-Rb receptor] connected to the JAK2/ 
/STAT3 cell signalling pathway [6]. 
In the present study, we investigated serum pro-
hepcidin concentration and iron status indices in 
obese elderly individuals. We observed that 62% of 
obese persons had normocytic or microcytic anaemia. 
Our findings seem to agree with recent studies which 
indicate that anaemia in the elderly is a common medi-
Figure 1. Spearman’s correlation analysis of serum prohepcidin 
with %FM in the group of obese individuals. %FM — fat mass 
percentage; p — significance level, Spearman r
Rycina 1. Analiza korelacji Spearmana pomiędzy surowiczą 
prohepcydyną a %FM w grupie otyłych osób
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cal problem [31]. Epidemiological studies show that 
the prevalence of anaemia increases with age, with 
a marked increase above the age of 60 [32]. 
In our study, we observed significantly increased 
circulating prohepcidin in obese individuals compared 
to non-obese. Our findings seem to agree with the 
observations of Tussing-Humphreys et al. [33] who 
reported that obese premenopausal women have 
significantly higher serum hepcidin levels compared 
to nonobese women with similar serum parameters 
of iron status. Also del Giudice et al. [34] and Sanad 
et al. [35], in studies carried out in children aged 7–11 
years, observed a significantly higher concentration of 
hepcidin in the obese. The results suggest that body fat 
content does have an impact on prohepcidin and hep-
cidin concentration, and therefore on iron homeostasis. 
A strong argument in support of this thesis is a statisti-
cally significant correlation between prohepcidin and 
fat mass percentage (%FM) observed in the whole 
group of obese individuals. Increased prohepcidin 
concentration in obesity can be explained in the most 
part as a result of its synthesis by a large amount of 
adipocytes. In addition, we should not exclude a chronic 
low-grade inflammation state inducing prohepcidin 
production. In our preliminary study, CRP was only 
slightly elevated in the group of obese people with 
anaemia. However, ferritin was increased in all obese 
individuals. 
According to up-to-date research, the main factors 
regulating hepcidin expression in the liver are the 
stimuli signalling increased erythropoiesis i.e. hypoxia, 
and low transferrin saturation [20–21, 36–37]. 
The crucial problem for research, as well as clini-
cal purposes, is whether this regulatory mechanism 
occurs in all cells involved in hepcidin production 
(including adipocytes) or is limited to hepatocytes. 
Bekri et al. established the lack of a positive feed-
back mechanism within the adipose tissue to control 
hepcidin secretion as a reaction to a low transferrin 
saturation. This mechanism has been observed only 
in the liver cells colony [5]. On the other hand, the 
lack of restraining impact of hypoxia on hepcidin 
expression in cardiomyocytes of rats was observed by 
Merle et al. In this study, the researchers noticed that 
hypoxia resulted in a significant increase of hepcidin 
mRNA levels and the concentration of the hormone 
itself, within the cardiac muscle. In contrast, the liver 
hepcidin expression decreased as a reaction to hy-
poxia [37]. All the results suggest that factors related 
to anaemia, such as tissue hypoxia and a decrease 
in transferrin saturation, have a negative effect on 
hepcidin production only in the hepatocytes, and 
that the regulation of hepcidin expression is possi-
bly tissue-specific. Research indicates that hepcidin 
expression in adipose tissue is probably stimulated 
rather by inflammatory stimuli than by iron [38].
According to our research, obese individuals with 
anaemia had significantly lower iron levels and in-
creased EPO as a result of induced erythropoiesis, sec-
ondary to iron deficiency in its active metabolic pool. In 
this group, we observed significantly lower prohepcidin 
levels compared to obese individuals without anaemia, 
but higher compared to non-obese volunteers. 
This observation may have important clinical impli-
cations, i.e. it is well known that hepcidin expression is 
more than 100–700-fold higher in hepatocytes than in 
adipocytes [18, 33]. However, when adipose tissue mass 
is significantly increased, ‘adipose tissue-derived pool 
of hepcidin’ becomes relevant. Analysing the results 
of previous studies [5, 33–35, 39] it can be concluded 
that obesity, especially abdominal, may be associated 
with increased systemic hepcidin concentrations and 
iron dysregulation. In this case, anaemia accompanied 
by central obesity can have a negative impact on the 
course of the disease as well as the effectiveness of its 
treatment. 
Worth mentioning in our current study is the fact 
that there was no difference in prohepcidin concen-
tration between obese patients with anaemia and the 
control group (non-obese without anaemia). We suggest 
that two factors may have an impact on prohepcidin 
production in this study group (II): obesity and anae-
mia. Obesity, as we concluded in our previous study, 
increases prohepcidin concentration [40]. In contrast, 
anaemia related factors decrease hepatic prohepcidin 
expression [20, 21, 36, 37]. Such interaction, two oppo-
sitely acting factors, may lead to a state of balance in 
the level of circulating hepcidin (Fig. 2). As a result, in 
our group of obese patients with anaemia, prohepcidin 
levels were similar to values observed in the control 
group (non-obese without anaemia). 
A potential limitation of our preliminary study is the 
fact that we have measured a prohormone (prohepci-
Figure 2. Diagram of impact of obesity and anaemia on serum 
hepcidin levels
Rycina 2. Schemat oddziaływania otyłości i anemii na poziom 
surowiczej hepcydyny
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din) of an active peptide (hepcidin). Further studies 
including quantification of hepcidin are needed to 
completely clarify the relative impact of adipose tissue 
on circulating hepcidin concentrations. Future studies 
should be conducted on comparatively larger popula-
tions of obese elderly patients. 
It would also be very interesting to investigate 
whether long-term weight loss reduces inflammation 
and hepcidin concentration, consequently improving 
iron status in obese patients.
Conclusion
The results of our study suggest that obesity increases 
prohepcidin levels in elderly patients. Moreover, the 
coexistence of obesity and anaemia reduces prohepcidin 
levels to values observed in elderly non-obese patients 
without anaemia.
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